Press Room

Press Clipping / Mar 31, 2020

Covid-19: Hand sanitiser effort continues

Speciality Chemicals Magazine, March 31, 2020

Covid-19: Hand sanitizer donated by Hovione | Hovione

Chemical companies continue to invest in hand sanitiser in response to the Covid-19 pandemic. A large number of them are now producing in significant volumes.

Ineos, the largest European producer of the two key raw materials - isopropyl alcohol (IPA) and ethanol – has announced its intention to produce 1 million bottles of hand sanitiser/month from each of three newly built facilities in the UK, Germany and France.

As of the end of March, the company has hit its target of building the first plant near Middlesbrough, UK. It will supply hospitals free of charge “during the crisis period” and is in discussions with retailers.

Dow announced on 30 March that its sites at Auburn, Michigan; South Charleston, West Virginia; Seneffe, Belgium; and Hortolândia, Brazil “possess the necessary raw material handling, mixing and packaging capabilities and will produce hand sanitiser”. They join the site at Stade, Germany, which is already manufacturing it.

Dow, like Ineos, was already producing raw materials, said that it could adapt its capabilities for downstream production with “little to no impact to normal operations”. Auburn can produce 7 tonnes/week and similar volumes are expected at the other sites. Once all are at full production, the company expects to produce 200 tonnes.

All of the hand sanitiser that will be produced has been allocated, with the majority for donation to state and regional health systems and government agencies for distribution. It will also be distributed to Dow production sites to help protect frontline employees. The first deliveries are expected to begin in the first week of April.

Plant-based ingredients firm Roquette has adapted one of its pilot lines at its site in Lestrem, France, to manufacture about 5,000 litres/week of a hydro-alcoholic disinfectant solution. The first shipments were sent to Lille University Hospital Centre, the French Blood Donors Organisation and to other local health facilities, in coordination with the Hauts-de-France Regional Health Agency and the local authorities.

In Germany, Wacker donated 15,000 litres of hand sanitiser for the production of disinfectants to Bavarian hospitals and care facilities at the request of the state Ministry of Economic Affairs. The alcohol needed, 11,000 liters of 2-propanol, was transported from Nünchritz, Saxony, to the Gendorf chemical industry park in Bavaria to be mixed and sent to an official distribution centre.

Swiss pharmaceutical CMDO Siegfried is also supplying disinfectant in those regions where it operates production sites, including the Swiss cantons of Aargau and Valais and around Minden in Germany. “The service including delivery is free of charge to the extent possible,” the company said, adding that it will not supply private or commercial organisations.

Meanwhile, Croda International said that it has gifted enough glycerine to regular customers to manufacture five million 250 ml bottles of hand sanitiser, assuming 2% glycerine content. It is also donating saponin vaccine adjuvants to projects working on a vaccine. The company plans to review with customers where more glycerine could be gifted.

Similarly in the US, Amyris, which is in discussions for the testing of its fermentation-derived squalene as a vaccine adjuvant for a Covid-19 vaccine, has launched its own No Compromise Pipette Baby branded hand sanitiser. The company said that it “will not price its hand sanitiser at a premium, and plans to donate part of the supply to front-line health staffers and medical personnel”. It plans to produce 30,000 units in the first few weeks.

Portugal’s Hovione began producing IPA- and ethanol-based hand sanitiser to a WHO formulation at tonne-scale for itself when supplies were short, it has emerged. The company, another major pharmaceutical CDMO, is now supplying the material free to Portuguese hospitals. Volumes were expected to reach 30 tonnes by the end of the month.

Earlier in March, Lanxess added a second shift at its site in Sudbury, UK, to boost production of Vikron sanitiser. Earlier, BASF announced plans to produce hand sanitisers at Ludwigshafen and supply them to hospitals in the Rhine-Neckar metropolitan region. The company has now reallocated tonnes of raw materials, especially IPA, for making the sanitisers and secured legal official permission to make them.

Similarly, Huntsman and Syngenta began making hydro alcoholic solution to produce hand sanitiser at Monthey, Switzerland, for free-of-charge supply to hospitals and pharmacies in the Canton of Vaud and the General Hospital in Lausanne. Plans were to ramp up production to 3-5 tonnes/week. Arkema has repurpose da production line at its Rhône-Alpes Research Centre in order to make 20 tonnes/week of alcohol-based solution to be distributed free of charge for the mass restocking of public hospitals.

The effort is not limited to chemical companies, of course. Flavours and fragrance giant Firmenich has shifted production at La Plaine, Switzerland, to disinfectant solution, while luxury goods maker LVMH and many manufacturers and distillers of spirits on both sides of the Atlantic have also switched production.

 

Read the article at Specchemonline

 

 

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025